Dr. Pinilla-Ibarz on Choosing Second-line BTK Inhibitors in CLL

Video

In Partnership With:

Javier Pinilla-Ibarz, MD, PhD, discusses the factors that go into choosing the optimal second-line BTK inhibitors for patients with chronic lymphocytic leukemia.

Javier Pinilla-Ibarz, MD, PhD, senior member, head of Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the factors that go into choosing the optimal second-line BTK inhibitors for patients with chronic lymphocytic leukemia (CLL).

Although second-generation BTK inhibitors generally elicit more durable responses, all BTK inhibitors, such as acalabrutinib (Calquence) and zanubrutinib (Brukinsa), have class effects, including bleeding and hypertension, Pinilla-Ibarz says. While the possibility for cardiovascular effects may make these second-generation BTK inhibitors seem suboptimal for certain high-risk patients, other drugs being investigated in CLL may still cause similar adverse effects (AEs) in longer follow-up, Pinilla-Ibarz notes.

Since AEs are a possibility with all BTK inhibitors, even well tolerated ones such as ibrutinib (Imbruvica), closely monitoring patients throughout treatment is important, Pinilla-Ibarz explains. Fortunately, patients with CLL have a variety of treatment options, and alternatives exist for those who respond poorly to certain agents, Pinilla-Ibarz concludes.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
A panel of 6 experts on colorectal cancer